Acquired byMitsubishi Tanabe Pharma Corporation on Jul, 2017
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
NeuroDerm is a clinical-stage pharmaceutical company developing treatments for central nervous system disorders. The company's technology enables new routes of administration for existing drugs that may enhance their efficacy. NeuroDerm is developing a pipeline of products for patients with moderate-to-severe Parkinson's disease, including a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. NeuroDerm's LD/CD line of products includes ND0612L for patients with moderate Parkinson's disease, ND0612H for patients with severe Parkinson's disease, and ND0680 for the small subset of patients with severe Parkinson's disease whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.